Article

Fibrin adhesives another approach to epithelial ingrowth post-LASIK

Refractive surgeons can consider fibrin adhesives to prevent the recurrence of epithelial ingrowth after LASIK.

Reviewed by David R. Hardten, MD

Minnetonka, MN-Got adhesives? Adhesives for post-LASIK epithelial ingrowth, that is. 

The use of fibrin adhesives can help surgeons manage this common complication of LASIK surgery, which occurs in 0.5% to 15% of cases, said David R. Hardten, MD.

Recent: New drape speeds ophthalmic surgery

“Epithelial ingrowth is usually observed in the first few weeks, it may be nonprogressive or progressive, and in the most advanced stage it may result in flap melt,” said Dr. Hardten, Minnesota Eye Consultants, Minnetonka, MN.

Common signs of epithelial ingrowth are isolated nests or sheets of cells, decreased visual acuity, induced astigmatism on refraction, and irregular astigmatism on topography.

Two common treatments for epithelial ingrowth are removal and neodymium:YAG laser treatment, Dr. Hardten said.

Removal usually consists of lifting and scraping epithelial cells, using a blunt spatula and Merocel sponge, and then using ethanol to supplement complete removal. Neodymium: YAG laser treatment is helpful when there are stable pockets of ingrowth where the elevation of the cornea causes changes in comfort or vision, he explained.

More: How a slit beam enhances visualization with corneal opacities

To help prevent the recurrence of epithelial ingrowth, surgeons can consider suturing the flap edges, although Dr. Hardten has found that this can induce striae, irregular astigmatism, and require suture removal. This also has a longer recovery. The use of a fibrin adhesive application is useful for recurrent cases but also has a longer recovery.

Consider adhesives

 

Consider adhesives

Another treatment alternative is hydrogel adhesive applications, Dr. Hardten said.

One fibrin adhesive (Tisseel Fibrin Glue, Baxter) is a mix of fibrinogen and thrombin, but it also has a bovine fibrinolysis inhibitor. The product takes 8 to 10 minutes to dry so a bandage scleral contact lens can be placed; it dissolves in 10 to 14 days.

Recent: Postop keratometry not associated with night-vision problems

In a study that Dr. Hardten led with fibrin glue used after LASIK to treat epithelial ingrowth, there was no recurrence in 80% of eyes over an average 26 months of follow-up.1

Thirty-nine eyes from 38 patients were included in the retrospective case series. Five eyes (12.8%) had mild epithelial ingrowth, but it did not require removal; at the 3-month follow up, three eyes (7.7%) had significant epithelial ingrowth requiring removal and fibrin application. At the final follow-up, which occurred at a little over 2 years, 84.6% of eyes had corrected distance visual acuity of 20/25 or better, and 74.4% had 20/40 or better uncorrected distance visual acuity. Ninety-two percent of eyes had unchanged or improved corrected visual acuity.

Complicated cases

 

Two eyes in the study had flap amputation due to irregular astigmatism from pre-existing areas of flap melt that were still a problem; one eye had ectasia (also pre-existing) and subsequent Intacs placement (Addition Technology), and another eye had poor vision from glaucoma (also pre-existing), Dr. Hardten said.

More: Novel forceps design improves iris hook placement

“Any of the brands of fibrin adhesive may be a useful adjunct in epithelial ingrowth removal in complicated cases,” he said.

These fibrin adhesives may reduce the incidence of recurrent epi-ingrowth, and they are well tolerated with no associated complications. However, larger randomized studies would be helpful to determine safety and efficacy compared with primary removal or sutures, he said.

Dr. Hardten noted some researchers have described using hydrogel adhesives in cases that do not require as long of a time for retention of the adhesive.

Related: More about the new-generation presbyopia-correcting IOL

 

Reference

1. Hardten DR, Fahmy MM, Vora GK, Berdahl JP, Kim T. Fibrin adhesive in conjunction with epithelial ingrowth removal after laser in situ keratomileusis: long-term results. J Cataract Refract Surg. 2015;41:1400-1405.

 

David R. Hardten, MD

E: drhardten@mneye.com

This article was adapted from Dr. Hardten’s presentation during Cornea Day at the 2016 meeting of the American Society of Cataract and Refractive Surgery. Dr. Hardten has done research, consulting, or speaking for Abbott, Allergan, Calhoun Vision, CXL-USA, ESI, Humanoptics, Oculus, OSD, Quantel and TLCV. Some of the information may represent off-label uses of approved drug or devices.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.